Co-Authors
This is a "connection" page, showing publications co-authored by JOSEPH JANKOVIC and M ATASSI.
Connection Strength
1.714
-
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
Score: 0.289
-
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
Score: 0.152
-
Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. Immunol Lett. 2017 10; 190:257-264.
Score: 0.151
-
Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
Score: 0.142
-
Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
Score: 0.134
-
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
Score: 0.101
-
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
Score: 0.100
-
Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
Score: 0.099
-
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011 Jul; 216(7):782-92.
Score: 0.095
-
Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans. Autoimmunity. 2011 May; 44(3):167-76.
Score: 0.094
-
Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
Score: 0.082
-
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
Score: 0.081
-
A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007 Jan-Feb; 20(1):15-21.
Score: 0.072
-
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb; 44(5):1029-41.
Score: 0.069
-
Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov; 31(3-4):247-62.
Score: 0.053